Therapeutic Advances in Medical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
Ovarian cancer (OC) is the fifth most common cause of cancer death in women. Although significant progress has been made in the treatment of OC, the majority of patients experience disease recurrence and receive second-line and sometimes several lines of treatment. Here we review the options available for the treatment of recurrent disease and discuss how different agents are selected, combined and offered in a rationale sequence in the context of multidisciplinary care. We reviewed published work between 1990 and 2013 and meeting abstracts related to the use of chemotherapy and surgery in patients with recurrent ovarian c...
Source: Therapeutic Advances in Medical Oncology - September 2, 2014 Category: Cancer & Oncology Authors: Luvero, D., Milani, A., Ledermann, J. A. Tags: Reviews Source Type: research

Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy
Gastrointestinal stromal tumors (GISTs) are rare malignancies, and historically had a poor prognosis, with little benefit from traditional anticancer therapies. The management of GISTs has undergone a paradigm change in recent years with the detection of activating mutations in the majority of these tumors. This knowledge has led to the development of targeted treatments which have dramatically improved benefit rates and survival. The tyrosine kinase inhibitor, imatinib, has become the standard of care for both those with high-risk resected GIST, and as first-line therapy in metastatic GIST. However, some patients demonstr...
Source: Therapeutic Advances in Medical Oncology - September 2, 2014 Category: Cancer & Oncology Authors: Ferraro, D., Zalcberg, J. Tags: Reviews Source Type: research

Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications
Neoadjuvant therapy in human epidermal growth factor receptor 2 (HER2)-positive breast cancer is exactly the paradigm of targeted therapy and a suitable setting to develop and test rapidly novel therapies in early stages. Moreover, neoadjuvant approaches provide a significant source of tumour tissue to identify molecular heterogeneity and potential predictive biomarkers of response. The addition of trastuzumab to primary chemotherapy revolutionized the treatment of this tumour subtype, increasing pathological complete response rate (pCR) that, even with its limitations, has also been shown to be an early marker of survival...
Source: Therapeutic Advances in Medical Oncology - September 2, 2014 Category: Cancer & Oncology Authors: Pernas Simon, S. Tags: Reviews Source Type: research

Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential
In February 2013, ado-trastuzumab emtansine (T-DM1, Kadcyla®) received regulatory approval in the United States for treatment-refractory human epidermal growth factor receptor 2 (HER2) positive metastatic or locally advanced breast cancer based on results from EMILIA, a large phase III trial that compared standard of care lapatinib plus capecitabine to T-DM1. Several other studies have been reported in the metastatic setting and multiple trials are ongoing or planned in the neoadjuvant, adjuvant and advanced disease settings. Here we provide an updated and comprehensive review of clinical trials evaluating T-DM1, discu...
Source: Therapeutic Advances in Medical Oncology - September 2, 2014 Category: Cancer & Oncology Authors: Peddi, P. F., Hurvitz, S. A. Tags: Reviews Source Type: research

Isolated hepatic perfusion for patients with liver metastases
Up to 80% of colorectal, melanoma, and neuroendocrine liver metastases are unresectable due to excessive tumor burden. Isolated hepatic perfusion (IHP) administers intensive therapy to the liver while limiting systemic toxicity and thus may have an important role in the management of unresectable liver metastases. This review s describes the development of IHP, initial clinical results, open and percutaneous IHP techniques, and contemporary long-term treatment outcomes. IHP with melphalan or tumor necrosis factor α (TNFα) has been shown to achieve hepatic response rates of greater than 50% with progression-free...
Source: Therapeutic Advances in Medical Oncology - June 16, 2014 Category: Cancer & Oncology Authors: Reddy, S. K., Kesmodel, S. B., Alexander, H. R. Tags: Reviews Source Type: research

Castration-resistant prostate cancer: latest evidence and therapeutic implications
This article reviews the approved therapies for CRPC, the agents currently in late-phase clinical trials, and notable early-phase trials of novel therapies and their combinations, with particular attention to trials incorporating novel biomarkers and intermediate endpoints to better identify those men who may or may not benefit from specific therapies. (Source: Therapeutic Advances in Medical Oncology)
Source: Therapeutic Advances in Medical Oncology - June 16, 2014 Category: Cancer & Oncology Authors: Suzman, D. L., Antonarakis, E. S. Tags: Reviews Source Type: research

The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
The phosphoinositide 3 kinase (PI3K)/Akt/mammalian (or mechanistic) target of rapamycin (mTOR) pathway is a complicated intracellular pathway, which leads to cell growth and tumor proliferation and plays a significant role in endocrine resistance in breast cancer. Multiple compounds targeting this pathway are being evaluated in clinical trials. These agents are generally well tolerated and can be used in combination with targeted therapies, endocrine therapy or cytotoxic agents. The identification of subtypes of tumors more likely to respond to these therapeutics cannot be overemphasized, since breast cancer is a very hete...
Source: Therapeutic Advances in Medical Oncology - June 16, 2014 Category: Cancer & Oncology Authors: Paplomata, E., O'Regan, R. Tags: Reviews Source Type: research

Transfusions and patient burden in chemotherapy-induced anaemia in France
Conclusion: In France, CIA treatment with RBC transfusion is a time-consuming activity for patients that includes multiple trips to a medical facility, blood testing and the transfusion procedure itself. This burden is important to consider in the context of optimizing proactive monitoring and planning for supportive oncology care. (Source: Therapeutic Advances in Medical Oncology)
Source: Therapeutic Advances in Medical Oncology - June 16, 2014 Category: Cancer & Oncology Authors: Corey-Lisle, P. K., Desrosiers, M.-P., Collins, H., De La Orden, M., Payne, K. A., Levache, C. B., Dumont, P. Tags: Original Research Source Type: research

Treatment of older patients with colorectal cancer: a perspective review
In a continuously aging population, the burden of colorectal cancer (CRC) is rising among older patients. Despite the fact that almost half of the cases occur in patients over 75 years, this age group is subjected to disparities regarding diagnostic and therapeutic options. So far, exclusion of older patients from randomized clinical trials has resulted in a lack of evidence-based guidelines. Nevertheless, newer data from studies specifically targeting older patients and subgroup analyses indicate that proper treatment planning and specific medical and geriatric assessment can achieve a safe and beneficial treatment result...
Source: Therapeutic Advances in Medical Oncology - April 14, 2014 Category: Cancer & Oncology Authors: Kordatou, Z., Kountourakis, P., Papamichael, D. Tags: Reviews Source Type: research

Recent advances in the treatment of gastrointestinal stromal tumors
Constitutively activating mutations in the KIT and platelet-derived growth factor receptor α (PDGFRA) RTKs play a crucial role in the biology of gastrointestinal stromal tumors (GISTs), and this disease has served as an effective model for targeting gain-of-function kinase mutations in cancer. Imatinib has entered the clinical arena in the last decade and substantially improved the outcome in these formerly untreatable cancers. However, most advanced GISTs responding to imatinib progress within 2–3 years due to heterogeneous subclones harboring a range of imatinib-resistant secondary KIT mutations. Sunitinib, a...
Source: Therapeutic Advances in Medical Oncology - April 14, 2014 Category: Cancer & Oncology Authors: Serrano, C., George, S. Tags: Reviews Source Type: research

Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies
Bone and brain metastases are a very common secondary localization of disease in patients with lung cancer. The prognosis of these patients is still poor with a median survival of less than 1 year. Current therapeutic approaches include palliative radiotherapy and systemic therapy with chemotherapy and targeted agents. For bone metastasis, zoledronic acid is the most commonly used bisphosphonate to prevent, reduce the incidence and delay the onset of skeletal-related events (SREs). Recently, denosumab, a fully human monoclonal antibody directed against the receptor activator of nuclear factor B (RANK) ligand inhibiting the...
Source: Therapeutic Advances in Medical Oncology - April 14, 2014 Category: Cancer & Oncology Authors: D'Antonio, C., Passaro, A., Gori, B., Del Signore, E., Migliorino, M. R., Ricciardi, S., Fulvi, A., de Marinis, F. Tags: Reviews Source Type: research

Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers
Triple-negative breast cancer (TNBC) represents a challenge clinically due to a lack of response to hormonal and HER2-targeted agents coupled with an aggressive disease course. As the biology of this breast cancer subtype is better understood, it is clear that TNBC is a heterogeneous disease and one targeted therapy is unlikely to be active in all patients. Biomarkers predictive of response to treatment are thus of great importance in TNBC. This review outlines studies evaluating biomarkers predictive of response to neoadjuvant chemotherapy and to targeted therapies in the advanced setting. The development of validated bio...
Source: Therapeutic Advances in Medical Oncology - April 14, 2014 Category: Cancer & Oncology Authors: Davis, S. L., Eckhardt, S. G., Tentler, J. J., Diamond, J. R. Tags: Reviews Source Type: research